RT Journal Article
SR Electronic
T1 Significantly elevated antibody levels and neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA booster vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.07.21267179
DO 10.1101/2021.12.07.21267179
A1 David H. Canaday
A1 Oladayo A. Oyebanji
A1 Elizabeth White
A1 Debbie Keresztesy
A1 Michael Payne
A1 Dennis Wilk
A1 Lenore Carias
A1 Htin Aung
A1 Kerri St. Denis
A1 Maegan L. Sheehan
A1 Sarah D. Berry
A1 Cheryl M. Cameron
A1 Mark J. Cameron
A1 Brigid M. Wilson
A1 Alejandro B. Balazs
A1 Christopher L. King
A1 Stefan Gravenstein
YR 2021
UL http://medrxiv.org/content/early/2021/12/07/2021.12.07.21267179.abstract
AB Nursing home (NH) residents have experienced significant morbidity and mortality to SARS-CoV-2 throughout the pandemic. Vaccines initially curbed NH resident morbidity and mortality, but antibody levels and protection have declined with time since vaccination, prompting introduction of booster vaccination. This study assesses humoral immune response to booster vaccination in 85 NH residents and 44 health care workers (HCW) that we have followed longitudinally since initial SARS-CoV-2 BNT162b2 mRNA vaccination. The findings reveal that booster vaccination significantly increased anti-spike, anti-receptor binding domain, and neutralization titers above the pre-booster levels in almost all NH residents and HCW to significantly higher levels than shortly after the completion of the initial vaccine series. These data support the CDC recommendation to offer vaccine boosters to HCWs and NH residents on an immunological basis. Notably, even the older, more frail and more multi-morbid NH residents have sizable antibody increases with boosting.Competing Interest StatementS. G. and D. H. C. are recipients of investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines and Sanofi Pasteur and Seqirus to study influenza vaccines. S. G. also does consulting for Seqirus, Sanofi, Merck, Vaxart, Novavax, Moderna and Janssen; has served on the speakers bureaus for Seqirus and Sanofi; and reports personal fees from Pfizer and data and safety monitoring board (DSMB) fees from Longevoron and SciClone. D. H. C. has done consulting work for Seqirus.Funding StatementThis work was funded by NIH AI129709-03S1, CDC 200-2016-91773, U01 CA260539-01, and VA BX005507-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study approval was obtained from the New England Institutional Review Board for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.